Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation

Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the factors associated with poor prognosis for patients with AML
  • Discuss the potential benefits of the use of several therapies to treat patients with FLT3-ITD mutations
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
05/13/2015
Course expires: 
05/13/2016
Cost:
$0.00

Smith Giri, MBBS
Department of Medicine
University of Tennessee Health Science Center
Memphis, Tennessee

Shadi Hamdeh, MD
Department of Internal Medicine
Creighton University Medical Center
Omaha, Nebraska

Vijaya Raj Bhatt, MBBS
Department of Internal Medicine, Division of Hematology and Oncology,
University of Nebraska Medical Center
Omaha, Nebraska

James K. Schwarz, MD
Department of Internal Medicine, Division of Hematology and Oncology,
University of Nebraska Medical Center
Omaha, Nebraska

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Accreditation Period

Course opens: 
05/13/2015
Course expires: 
05/13/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing